US-China Biomedical Technology, Inc. (UCBB) financial statements (2021 and earlier)

Company profile

Business Address 2 PARK PLAZA, SUITE 400
IRVINE, CA 92614
State of Incorp. NV
Fiscal Year End February 28
SIC 7311 - Advertising Agencies (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

5/31/2019
Q1
2/28/2019
Q4
11/30/2018
Q3
8/31/2018
Q2
5/31/2018
Q1
2/28/2018
Q4
11/30/2017
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments14237211340459560
Cash and cash equivalents14237211340459560
Prepaid expense13229131855
Total current assets:15558220353477615
Noncurrent Assets
Operating lease, right-of-use asset314 
Deposits noncurrent assets191919191919 
Total noncurrent assets:3331919191919 
TOTAL ASSETS:48877239372496815
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:302824402346145
Accounts payable182224402318111
Employee-related liabilities126   2861
Other undisclosed accounts payable and accrued liabilities      (26)
Debt183    457
Deferred rent credit 8742 
Due to related parties22333333261 
Other undisclosed current liabilities40      
Total current liabilities:25438647859352152
Noncurrent Liabilities
Long-term debt and lease obligation140      
Operating lease, liability140 
Total noncurrent liabilities:140      
Other undisclosed liabilities 39    192
Total liabilities:39576647859352345
Stockholders' equity
Stockholders' equity attributable to parent931175295438(272)(340)
Common stock20161616161413
Additional paid in capital3,1332,9232,9232,9232,9231,9411,797
Accumulated deficit(3,059)(2,937)(2,763)(2,643)(2,500)(2,226)(2,150)
Total stockholders' equity:931175295438(272)(340)
TOTAL LIABILITIES AND EQUITY:48877239372496815

Income statement (P&L) ($ in thousands)

5/31/2019
Q1
2/28/2019
Q4
11/30/2018
Q3
8/31/2018
Q2
5/31/2018
Q1
2/28/2018
Q4
11/30/2017
Q3
Revenues     (10) 
Operating expenses(122)(173)(119)(143)(275)(117)(129)
Other undisclosed operating loss     (10) 
Operating loss:(122)(173)(119)(143)(275)(127)(129)
Nonoperating expense
(Other Nonoperating expense)
(1)      
Interest and debt expense(1)184  (184)42(3)
Other undisclosed loss from continuing operations before equity method investments, income taxes (188)     
Loss from continuing operations before equity method investments, income taxes:(123)(177)(119)(143)(459)(85)(132)
Other undisclosed income from continuing operations before income taxes14  18410 
Loss from continuing operations before income taxes:(123)(173)(119)(143)(275)(75)(132)
Other undisclosed loss from continuing operations (1)   (1) 
Net loss available to common stockholders, diluted:(123)(174)(119)(143)(275)(76)(132)

Comprehensive Income ($ in thousands)

5/31/2019
Q1
2/28/2019
Q4
11/30/2018
Q3
8/31/2018
Q2
5/31/2018
Q1
2/28/2018
Q4
11/30/2017
Q3
Net loss:(123)(174)(119)(143)(275)(76)(132)
Comprehensive loss, net of tax, attributable to parent:(123)(174)(119)(143)(275)(76)(132)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: